INTEC PHARMA LTD. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-08-09: Form 8-K; Period of report 2021-08-03; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events; Details 3.01.
- 2021-07-29: Form 8-K; Period of report 2021-07-23; Description 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events; Details 2.01.
- 2021-07-23: Form 8-K; Period of report 2021-07-23; Description 8.01 Other Events; Details 8.01.
- 2021-07-16: Form 8-K; Period of report 2021-07-13; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-08-09 | 8-K | 2021-08-03 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 8.01 Other Events | 3.01 In connection with the Merger (as defined below) and the previously announced domestication merger (which was consummated on July 27, 2021 and was one of the closing conditions of the Merger), after which Intec Pharma Ltd., an Israeli company (the “Company”), became a wholly owned subsidiary of Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc.), a Delaware corporation (“Indaptus”), a request was made for the Nasdaq Stock Market LLC to file with the Securities and Exchange Commission (the “SEC”) an application on Form 25 to delist and deregister the ordinary shares of the Company under Section 12(b) of the Securities Exchange Act of 1934, as amended. 8.01 On August 3, 2021, Indaptus completed its business combination with Decoy Biosystems, Inc., a Delaware corporation (“Decoy”) following the satisfaction or waiver of the conditions set forth in the Agreement and Plan of Merger, dated as of March 15, 2021 among Indaptus, the Company, and Dillon Merger Subsidiary Inc., a Delaware corporation and wholly owned subsidiary of Indaptus (“Merger Sub”) pursuant to which Merger Sub merged with and into Decoy, with Decoy surviving as a wholly owned subsidiary of Indaptus (the “Merger”). | form8-k.htm |
| 2021-07-29 | 8-K | 2021-07-23 | 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 2.01 On July 27, 2021, Intec Pharma Ltd., an Israeli company (the “Company” or “Intec Israel”), Intec Parent, Inc., a Delaware corporation (“Intec Parent”), and Domestication Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of Intec Parent (the “Domestication Merger Sub”), completed the previously announced domestication merger pursuant to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated April 27, 2021 (the “Domestication Merger Agreement”), whereby Domestication Merger Sub merged with and into Intec Israel, with Intec Israel being the surviving entity and a wholly-owned subsidiary of Intec Parent (the “Domestication Merger”). 3.01 The information set forth in Item 2.01 above and Items 3.03, 5.01 and 5.03 below of this Current Report on Form 8-K is incorporated herein by reference. 3.03 The information set forth in Item 2.01 and 3.01 above and Item 5.03 below of this Current Report on Form 8-K is incorporated herein by reference. 5.03 The information set forth in Items 2.01, 3.01 and 3.03 above of this Current Report on Form 8-K is incorporated herein by reference. 8.01 On July 23, 2021, Intec Parent entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”), pursuant to which Intec Parent agreed to sell and issue, in a private placement (the “Private Placement”) a pre-funded warrant to purchase up to 2,727,273 shares of Intec Parent’s common stock (the “Pre-funded Warrant”) and a warrant to purchase up to 2,727,273 of Intec Parent’s common stock (the “Warrant” and together with the “Pre-funded Warrant” and the shares of common stock underlying the Warrant and Pre-funded Warrant, the “Securities”), at a purchase price of $10.99 per Pre-funded Warrant and associated Warrant, for aggregate gross proceeds to Intec Parent of approximately $29.9 million (or approximately $30.0 million assuming the full exercise of the Pre-funded Warrant), before deducting the placement agent’s fees and other estimated offering expenses payable by Intec Parent. | form8-k.htm |
| 2021-07-23 | 8-K | 2021-07-23 | 8.01 Other Events | 8.01 As of July 23, 2021, the authorized share capital of Intec Pharma Ltd., as Israeli company (the “Company”), is 17.5 million ordinary shares, of which 7,370,883 ordinary shares are outstanding. | form8-k.htm |
| 2021-07-16 | 8-K | 2021-07-13 | 8.01 Other Events | 8.01 Intec Pharma Ltd. (the “Company”), the directors of the Company (the “Intec Board”), Intec Parent, Inc., Dillion Merger Subsidiary, Inc., Decoy Biosystems, Inc (“Decoy”) and Domestication Merger Sub Ltd. (collectively, “Defendants”) were named as defendants in connection with the following actions: St. Hilarie v. | form8-k.htm |
| 2021-06-22 | 8-K | 2021-06-21 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 21, 2021, Intec Pharma Ltd. (the “Company” or “Intec Israel”) held a special meeting of shareholders (the “Special Meeting”) to consider seven proposals related to the Company’s merger with Decoy Biosystems, Inc., a Delaware corporation (“Decoy”), in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2021 (the “Merger Agreement”) among the Company, Intec Parent, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Intec Parent”), Dillon Merger Subsidiary Inc., a Delaware corporation (“Merger Sub”), Domestication Merger Sub, Ltd., an Israeli company and a wholly-owned subsidiary of Intec Parent (“Domestication Merger Sub”), and Decoy. | form8-k.htm |
| 2021-04-30 | 8-K | 2021-04-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8-k.htm |
| 2021-03-15 | 8-K | 2021-03-15 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 On March 15, 2021, the Company and Decoy issued a joint press release announcing the execution of the Merger Agreement. | ea137630-8k_intecpharma.htm |
| 2021-02-08 | 8-K | 2021-02-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 2, 2021, Dr. Nadav Navon, the Chief Operating Officer of Intec Pharma Ltd. (the “Company”), notified the Company of his resignation as Chief Operating Officer of the Company, effective May 1, 2021, in order to pursue a new opportunity. | ea134808-8k_intecpharma.htm |
| 2020-12-09 | 8-K | 2020-12-09 | 8.01 Other Events | 8.01 On December 9, 2020, Intec Pharma Ltd. issued a press release titled “Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma”. | ea131278-8k_intecpharma.htm |
| 2020-11-05 | 8-K | 2020-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2020, Intec Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results of operations for the third quarter ended September 30, 2020. | ea129358-8k_intecpharma.htm |
| 2020-10-29 | 8-K | 2020-10-29 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 3.03 To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this report is incorporated herein by reference. 5.03 As previously disclosed, on July 15, 2020, Intec Pharma Ltd. (the “Company”) held its annual meeting of shareholders (the “Annual Meeting”). 8.01 On October 29, 2020, the Company announced the 1-for-20 Reverse Share Split that is scheduled to become effective after trading closes on October 29, 2020. | ea129072-8k_intecpharma.htm |
| 2020-10-08 | 8-K | 2020-10-08 | 8.01 Other Events | 8.01 On October 8, 2020, Intec Pharma Ltd. issued a press release titled “Intec Pharma Announces New Research Collaboration Agreement with MSD”. | ea127978-8k_intecpharma.htm |
| 2020-10-02 | 8-K | 2020-10-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 1, 2020, Intec Pharma Ltd. (the “Company”), notified its Chief Medical Officer, Dr. R. Michael Gendreau, that his employment with the Company would be terminated, effective as of October 31, 2020. | ea127729-8k_intecpharma.htm |
| 2020-09-18 | 8-K | 2020-09-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 16, 2020, the Board of Directors of Intec Pharma Ltd. (the “Company”), upon recommendation of its Compensation Committee, approved an executive retention award to each of Nir Sassi, the Company’s Chief Financial Officer and Walt A. Linscott, the Company’s Chief Business Officer, of 100,000 options to purchase ordinary shares of the Company pursuant to the Company’s 2015 Equity Incentive Plan. | ea127053-8k_intecpharma.htm |
| 2020-08-10 | 8-K | 2020-08-07 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | ea125186-8k_intecpharma.htm |
| 2020-08-05 | 8-K | 2020-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2020, Intec Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results of operations for the second quarter ended June 30, 2020. | ea124882-8k_intecpharma.htm |
| 2020-07-17 | 8-K | 2020-07-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On July 15, 2020, the shareholders of Intec Pharma Ltd. (the “Company”) approved at the 2020 annual meeting of shareholders of the Company (the “Annual Meeting”) an amendment to its 2015 Equity Incentive Plan (the “2015 Plan”) to increase the number of ordinary shares authorized for issuance under the 2015 Plan by 3,500,000 ordinary shares. 5.07 On July 15, 2020, the Company held its Annual Meeting. | ea124295-8k_intecpharma.htm |
| 2020-06-08 | 8-K | 2020-06-08 | 5.08 Shareholder Director Nominations | 5.08 On June 8, 2020, Intec Pharma Ltd. (the “Company”) established July 15, 2020, as the date for the Company’s 2020 Annual Meeting of Shareholders (the “Annual Meeting”). | ea122790-8k_intecpharma.htm |
| 2020-05-11 | 8-K | 2020-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2020, Intec Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results of operations for the first quarter ended March 31, 2020. | ea121621-8k_intecpharma.htm |
| 2020-05-06 | 8-K | 2020-05-04 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information under Item 1.01 of this Current Report on Form 8-K regarding the warrants and the Ordinary Shares issuable upon exercise of the warrants is incorporated herein by reference. 8.01 Pursuant to that certain Sales Agreement, dated March 1, 2019 (the “Sales Agreement”), by and between the Company and Cowen and Company, LLC, the Company may elect from time to time, to offer and sell ordinary shares through an “at the market offering” as defined in Rule 415(a)(4) (the “ATM Offering”) promulgated under the Securities Act having an aggregate offering price of up to $75,000,000. | ea121430-8k_intecpharma.htm |
| 2020-03-13 | 8-K | 2020-03-13 | 2.02 Results of Operations and Financial Condition | 2.02 On March 13, 2020, Intec Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results of operations for the fourth quarter and fiscal year ended December 31, 2019. | ea119549-8k_intecpharma.htm |
| 2020-02-03 | 8-K | 2020-01-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 On January 30, 2020, Intec Pharma Ltd. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC (the “Underwriter”), relating to the offering, issuance and sale of (i) 15,280,000 ordinary shares and accompanying warrants to purchase 15,280,000 ordinary shares, and (ii) pre-funded warrants to purchase up to an aggregate of 970,000 ordinary shares and accompanying warrants to purchase up to an aggregate of 970,000 ordinary shares. | f8k013020_intecpharma.htm |
| 2019-12-11 | 8-K | 2019-12-11 | 8.01 Other Events | 8.01 On December 11, 2019, Intec Pharma Ltd. issued a press release titled “Intec Pharma Provides Update on Novartis Feasibility and Option Agreement”. | f8k121119_intecpharma.htm |
| 2019-12-03 | 8-K | 2019-12-02 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 Entry into a Material Definitive Agreement. 7.01 On December 3, 2019, the Company issued a press release announcing that it has entered into the Purchase Agreement with Aspire Capital. | f8k120219_intecpharma.htm |
| 2019-12-02 | 8-K | 2019-12-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On December 2, 2019, the shareholders of Intec Pharma Ltd. approved at the 2019 annual meeting of shareholders of the Company (the “Annual Meeting”) an amendment to its 2015 Equity Incentive Plan (the “2015 Plan”) to increase the number of ordinary shares authorized for issuance under the 2015 Plan by 1,000,000 ordinary shares. 5.07 On December 2, 2019, the Company held its Annual Meeting. | f8k120219b_intecpharma.htm |
| 2019-11-12 | 8-K | 2019-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2019, Intec Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results of operations for the third quarter ended September 30, 2019. | f8k111219_intecpharma.htm |
| 2019-09-27 | 8-K | 2019-09-24 | 5.08 Shareholder Director Nominations | 5.08 On September 24, 2019, the board of directors of Intec Pharma Ltd. (the “Company”) established December 2, 2019, as the date for the Company’s 2019 Annual Meeting of Shareholders (the “Annual Meeting”). | f8k092419_intecpharma.htm |
| 2019-09-16 | 8-K | 2019-09-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 13, 2019, the Board of Directors of Intec Pharma Ltd. (the “Company”), upon recommendation of its Compensation Committee, approved (i) an executive retention award to Nir Sassi, the Company’s Chief Financial Officer, of 200,000 options to purchase ordinary shares of the Company pursuant to the Company’s 2015 Equity Incentive Plan and a guaranteed bonus of 100% of his target annual bonus (i.e. $56,000), and (ii) an executive retention award to Walt A. Linscott, the Company’s Chief Business Officer, of 200,000 options to purchase ordinary shares of the Company pursuant to the Company’s 2015 Equity Incentive Plan and a guaranteed bonus of 100% of his target annual bonus (i.e. $170,000). | f8k091319_intecpharma.htm |
| 2019-09-09 | 8-K | 2019-09-09 | 7.01 Regulation FD Disclosure | 7.01 On September 9, 2019, Intec Pharma Ltd. (the “Company”) updated its corporate presentation that it intends to use in conferences and meetings with investors from time to time. | f8k090919_intecpharmaltd.htm |
| 2019-09-05 | 8-K | 2019-09-03 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On September 3, 2019, Intec Pharma Ltd. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. | f8k090319_intecpharmaltd.htm |
| 2019-08-09 | 8-K | 2019-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2019, Intec Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results of operations for the second quarter ended June 30, 2019. | f8k080919_intecpharma.htm |
| 2019-07-22 | 8-K | 2019-07-22 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On July 22, 2019, management of Intec Pharma Ltd. (the “Company”) will hold a conference call and webcast at 8:30 a.m. 8.01 On July 22, 2019, the Company issued a press release announcing top-line results from its Phase III ACCORDANCE clinical trial of AP-CD/LD, a multi-center, global, randomized, double-blind, double-dummy, active-controlled, parallel-group study in adult subjects with advanced Parkinson’s Disease. | f8k072219_intecpharma.htm |
| 2019-05-07 | 8-K | 2019-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2019, Intec Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results of operations for the first quarter ended March 31, 2019. | f8k050719_intecpharma.htm |
| 2019-04-05 | 8-K | 2019-04-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On April 26, 2019, the term of office of each of Gil Bianco and Issac Silberman as a director of Intec Pharma Ltd. (the “Company”) is set to expire. 5.07 On April 4, 2018, the Company held a special meeting of shareholders (the “Special Meeting”). | f8k040219_intecpharma.htm |
| 2019-03-04 | 8-K | 2019-03-04 | 7.01 Regulation FD Disclosure | 7.01 Intec Pharma Ltd. (the “Company”) is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a slide presentation with respect to the Company’s recently completed Accordion Pill Carbidopa/Levodopa three times daily PK study which the Company intends to use at key opinion leader events and at meetings with the investor community. | f8k030419_intecpharma.htm |
| 2019-02-27 | 8-K | 2019-02-27 | 2.02 Results of Operations and Financial Condition | 2.02 On February 27, 2019, Intec Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results of operations for the fourth quarter and fiscal year ended December 31, 2018. | f8k022719_intecpharmaltd.htm |
| 2019-01-25 | 8-K | 2019-01-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 22, 2019, the Board of Directors of Intec Pharma Ltd. (the “Company”), upon recommendation of its Compensation Committee, approved (i) the payment of a 2018 cash performance bonus of $130,613, the grant of 90,000 options to purchase ordinary shares of the Company pursuant to the Company’s 2015 Equity Incentive Plan, an annual 2019 base salary of $340,000, and an annual discretionary bonus target for 2019 of 50% of annual base salary to Walt A. Linscott, the Company’s Chief Business Officer; and (ii) the payment of a 2018 cash performance bonus of $110,008, the grant 110,000 options to purchase ordinary shares of the Company pursuant to the Company’s 2015 Equity Incentive Plan, an annual 2019 base salary of $336,000, and an annual discretionary bonus target for 2019 of 40% of annual base salary to Dr. R. Michael Gendreau, the Company’s Chief Medical Officer. | f8k012219_intecpharma.htm |
| 2019-01-07 | 8-K | 2019-01-07 | 7.01 Regulation FD Disclosure | 7.01 On January 7, 2019, Intec Pharma Ltd. (the “Company”) updated its corporate presentation that it intends to use in conferences and meetings with investors from time to time. | s115222_8k.htm |
| 2019-01-02 | 8-K | 2019-01-01 | 8.01 Other Events | 8.01 As of June 30, 2018, the last business day of the second quarter of Intec Pharma Ltd. (the “Company”), the Company determined that it no longer qualified as a foreign private issuer. | s115133_8k.htm |